Explore 3 Stock Ideas & Industry Insights Download Free Report

Healthcare

Solvonis Therapeutics (SVNS): A High-Risk Main-Market Micro-Cap With a Phase 3 Addiction Programme — and a Funding Overhang

On 25 August 2026 Solvonis raised £1.3m gross in a placing at £0.0012 per share, a 14% discount to the prior close, appointing Turner Pope Investments as sole broker and adding a UK institutional investor to the register, taking shares in issue to around …

Divya Sood | 28 August 2026

GSK’s Pipeline vs Vaccine Challenge: What Could Drive the Next Big Move?

On 28 July 2026 GSK (LSE:GSK) reported second-quarter total sales of £8.4bn, up 5%, and core operating profit of around £2.8bn. The company raised its research ambition, now planning more than 20 Phase III trial starts in 2026 across sevenAssetsand 18 indications in oncology, …

Ankur Sharma | 28 August 2026

AstraZeneca’s Next Big Catalyst: Can Its Drug Pipeline Keep the FTSE Giant on Top?

In February 2026 AstraZeneca (LSE:AZN) began trading directly on the New York Stock Exchange, giving what it called “equal weight” to its UK, Swedish and US listings while keeping London as its primary listing — a move accompanying a reaffirmed pledge to invest $50bn …

Ankur Sharma | 28 August 2026

Kooth in Focus: Is Digital Mental Health Back in Favour With UK Investors?

Digital mental health has been a volatile place to invest, and Kooth (LSE: KOO) has embodied both the promise and the pitfalls. The company provides anonymous online mental-health support in the UK and, through its Soluna app, to young people across California under a …

Ankur Sharma | 28 August 2026

Shield Therapeutics Surges as It Takes Full US Control of ACCRUFeR

Commercial-stage pharmaceutical company Shield Therapeutics (AIM: STX) has handed the market a clear, fundamental catalyst. On 27 August 2026 it announced that it would take full commercial control of its lead product, the oral iron therapy ACCRUFeR, in the United States — and the …

Ankur Sharma | 28 August 2026

Smith & Nephew Faces a Leadership Test as Investors Reassess the Medtech Recovery

Smith & Nephew, the London-listed medical-technology group behind artificial hips and knees, sports-medicine tools and advanced wound-care dressings, has spent several years trying to convince investors that its long-promised turnaround is real. Its second-quarter and half-year results on 4 August 2026 delivered a mixed …

Ankur Sharma | 28 August 2026

ConvaTec's Medtech Growth Story Is Improving — Could the Market Still Be Underestimating It?

ConvaTec, the Reading-based FTSE 100 medical-technology group, has quietly transformed itself over the past few years from a sleepy chronic-care supplier into a more disciplined, faster-growing medtech business. Its products address unglamorous but essential needs — advanced wound care, ostomy care, continence care and …

Ankur Sharma | 28 August 2026

AstraZeneca's £193 Billion Question: Can the Drug Pipeline Keep Powering the Next Decade?

AstraZeneca is Britain's most valuable listed company, and with a market capitalisation in the region of £193 billion it carries an outsized influence over the FTSE 100. For all that heft, the investment case rests on a single, demanding proposition: that chief executive Pascal …

Ankur Sharma | 27 August 2026

GSK's Next Chapter: Can New Medicines Turn the Pharma Giant Into a Faster Growth Story?

GSK is opening a new chapter. After nearly a decade with Emma Walmsley at the helm — a period that saw the demerger of consumer-health business Haleon and a rebuilding of the pipeline — the FTSE 100 pharmaceutical group is transitioning to newLeadershipunder Luke …

Ankur Sharma | 27 August 2026

Haleon at £33 Billion: Why Consumer Health May Be One of Britain's Quietest Growth Themes

Haleon does not generate the headlines of a Diageo or a Vodafone, but the consumer-health group spun out of GSK in 2022 has become one of the FTSE 100's steadier performers. The owner of Sensodyne, Panadol, Centrum, Voltaren, Advil and parodontax sits at the …

Ankur Sharma | 27 August 2026
Support

Hi! How can we help you today?

Loading…